Evidence map›Paper›PMID 40822897›Full record

ArticleInternational journal of general medicine2025

Levels of Sestrin-1 in Rheumatoid Arthritis Patients: Exploring the Association with Atherosclerosis.

Ahmet Lutfu Sertdemir, Ahmet Taha Sahin, Yunus Emre Yavuz, Selman Parlak, Abdullah Icli, Serhat Kesriklioglu

Abstract read
In one paragraph

Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmet Lutfu SertdemirDepartment of Cardiology, Necmettin Erbakan University School of Medicine, Konya, Turkiye.
Ahmet Taha SahinDepartment of Cardiology, Beyhekim Training and Research Hospital, Konya, Turkiye.
Yunus Emre YavuzDepartment of Cardiology, Siirt Training and Research Hospital, Siirt, Turkiye.
Selman ParlakDepartment of Rheumatology, Beyhekim Training and Research Hospital, Konya, Turkiye.
Abdullah IcliDepartment of Cardiology, Necmettin Erbakan University School of Medicine, Konya, Turkiye.
Serhat KesrikliogluDepartment of Cardiology, Necmettin Erbakan University School of Medicine, Konya, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rheumatoid arthritis (RA) is an autoimmune disease and affects various parts of the body, especially the joints, through inflammation. Sestrins are molecules that are known to have anti-inflammatory properties and have been shown to play a role in the stress response in the body. Methods: Our study is an observational study. Fifty-five RA patients followed in the Rheumatology outpatient clinic and 55 control groups with similar demographic characteristics to this patient group were included in the study. The disease activity scores, cardiac parameters and Sestrin-1 levels of the participants were measured and both groups were compared. Results: There were no differences observed between the two groups in demographic characteristics. Right Carotid intima media thickness (CIMT) levels were found to be significantly higher in RA patients (p = 0.036). Sestrin-1 levels were determined to be significantly lower in RA patients compared to the control group (p<0.001). According to multivariate analysis results, a 1 unit decrease in Sestrin-1 measurement reduces the risk of RA by 0.633 times (p = 0.031). Conclusion: Our study is the first to show that decreasing of Sestrin-1 may play a potential role of subclinical atherosclerosis in RA patients. However, the nature of this relationship and the potential role of Sestrin-1 in the treatment of RA still requires further investigation.

Indexed as

atherosclerosisrheumatoid arthritisSestrin-1

Identifiers

PMID40822897
PMCPMC12357101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.